|Bid||5.78 x 3000|
|Ask||5.86 x 800|
|Day's Range||5.63 - 5.92|
|52 Week Range||1.43 - 7.80|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.41|
Subscribe to Yahoo Finance Plus to view Fair Value for CTIC
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC). This is CTI's drug that was approved by the Food and Drug Administration (FDA) in March for the treatment of myelofibrosis, a rare bone marrow disorder.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022.